CYCC - מקדם החזר מותאם קצב צמיחה Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals (CYCC) is optimizing costs through flexible global supply chains for active substances. The financial model relies on grants and partnerships to develop leukemia treatments. The current PEG ratio clearly confirms the market valuation, where the actual value is 0.00. However, a liquidity deficit and uncertainty regarding fadraciclib test outcomes create significant risks for investors.
פילוחי מדדים ואנליטיקה של חברת Cyclacel Pharmaceuticals (CYCC)
The PEG ratio compares the current market multiple with net income growth, allowing for the determination of an asset's undervaluation relative to its expansion. While analyzing the current PEG level helps identify growth potential, for Cyclacel Pharmaceuticals (CYCC), this metric remains speculative, as the company is in the early stages of clinical trials and finances its operations through securities issuance.
